Clinical Cancer Research

Table of Contents

May 1, 2015 • Volume 21 • Number 9

Highlights of This Issue 1973

SPECIAL FEATURES

CCR 20th Anniversary Commentary

1975  CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
Sami I. Bashour and Nuhad K. Ibrahim

CCR Translations

1978  PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos
See related article, p. 2138

1981  The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse
Saar Gill
See related article, p. 2020

CCR New Strategies

1984  New Strategies in Glioblastoma: Exploiting the New Biology
Howard A. Fine

Molecular Pathways

1989  Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Lynnette Fernandez-Cuesta and Roman K. Thomas

1995  Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy
Efficacy via Reduction in Oxygen Demand
Alexander Lin and Amit Maity

Reviews

2001  Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

2009  Genomic Landscape of Human Papillomavirus–Associated Cancers
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

CANCER THERAPY: CLINICAL

2020  Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
See related commentary, p. 1981

PERSONALIZED MEDICINE AND IMAGING

2029  Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jasswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blank, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

2038  Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiacer

2045  Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Brian Parkin, Peter Ouillette, Mehmet Yildiz, Kamliai Saiya-Cork, Kerby Shedden, and Sami N. Malek

Downloaded from clincancerres.aacrjournals.org on April 12, 2017. © 2015 American Association for Cancer Research.
Preclinical Pharmacologic Evaluation of Targeting Notch Signaling with a Notch2/Notch3 CD47 Enhances PTEN Loss Is Associated with Worse Outcome in MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Functionality of Artificial Antigen-Presenting Cells

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

CHEMOTHERAPY: PRECLINICAL

CHEMOTHERAPY: PRECLINICAL

PRECLINICAL PHARMACOLOGIC EVALUATION OF TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 CD47

PTEN LOSS IS ASSOCIATED WITH WORSE OUTCOME IN HER2-AMPLIFIED BREAST CANCER PATIENTS BUT IS NOT ASSOCIATED WITH TRASTUZUMAB RESISTANCE

TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 ANTAGONIST (TAREXTUMAB) INHIBITS TUMOR FUNCTIONALITY OF ARTIFICIAL ANTIGEN-PRESENTING CELLS

TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 ANTAGONIST (TAREXTUMAB) INHIBITS TUMOR GROWTH AND DECREASES TUMOR-INITIATING CELL FREQUENCY

PRECLINICAL PHARMACOLOGIC EVALUATION OF PRALATREXATE AND ROMIDEPSIN CONFIRMS POTENT SYNERGY OF THE COMBINATION IN A MURINE MODEL OF HUMAN T-CELL LYMPHOMA

2075 CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Heiko Bruns, Catherine Bessell, Juan Carlos Varela, Carl Haupt, Jerry Fang, Shirin Pasemann, Andreas Mackensen, Mathias Oelke, Jonathan P. Schneck, Carl Haupt, Jerry Fang, Shirin Pasemann, Andreas Mackensen, Mathias Oelke, Jonathan P. Schneck, and Christian Schütz

2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Functionality of Artificial Antigen-Presenting Cells
Wan-Ching Yen, Marcus M. Fischer, Fumiko Axellod, Christopher Bond, Jennifer Cain, Austin Gurney, and Tracy Tang, Breanna Wallace, Min Wang, Chun Zhang, William R. Henner, Rene Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hising, Guido Reifenberger, and Wolfgang Wick for the DIRECTOR Study Group

2096 Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

CANCER THERAPY: PRECLINICAL

CHEMOTHERAPY: PRECLINICAL

PRECLINICAL PHARMACOLOGIC EVALUATION OF TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 CD47

PTEN LOSS IS ASSOCIATED WITH WORSE OUTCOME IN HER2-AMPLIFIED BREAST CANCER PATIENTS BUT IS NOT ASSOCIATED WITH TRASTUZUMAB RESISTANCE

TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 ANTAGONIST (TAREXTUMAB) INHIBITS TUMOR FUNCTIONALITY OF ARTIFICIAL ANTIGEN-PRESENTING CELLS

TARGETING NOTCH SIGNALING WITH A NOTCH2/NOTCH3 ANTAGONIST (TAREXTUMAB) INHIBITS TUMOR GROWTH AND DECREASES TUMOR-INITIATING CELL FREQUENCY

PRECLINICAL PHARMACOLOGIC EVALUATION OF PRALATREXATE AND ROMIDEPSIN CONFIRMS POTENT SYNERGY OF THE COMBINATION IN A MURINE MODEL OF HUMAN T-CELL LYMPHOMA

2075 CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Heiko Bruns, Catherine Bessell, Juan Carlos Varela, Carl Haupt, Jerry Fang, Shirin Pasemann, Andreas Mackensen, Mathias Oelke, Jonathan P. Schneck, and Christian Schütz

2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Functionality of Artificial Antigen-Presenting Cells
Wan-Ching Yen, Marcus M. Fischer, Fumiko Axellod, Christopher Bond, Jennifer Cain, Austin Gurney, and Tracy Tang, Breanna Wallace, Min Wang, Chun Zhang, William R. Henner, Rene Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hising, Guido Reifenberger, and Wolfgang Wick for the DIRECTOR Study Group

2096 Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

BIOLOGY OF HUMAN TUMORS

2078 CHEMOTHERAPY RESCUES HYPOXIC TUMOR CELLS AND INDUCES THEIR REOXGENATION AND REPOPULATION—AN EFFECT THAT IS INHIBITED BY THE HYPOXIA-ACTIVATED PRODRUG TH-302
Jasdeep K. Saggar and Ian F. Tannock

2081 TARGETED AXL INHIBITION PRIMES CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS TO APOPTOSIS AND SHOWS SYNERGISTIC/ADDITIVE EFFECTS IN COMBINATION WITH BTK INHIBITORS

2087 RAC1/PAK1/P38/MMP-2 AXIS REGULATES ANGIogenesis IN Ovarian Cancer
Vianey Gonzalez-Villasana, Enrique Fuentes-Mattei, Cristina Ivan, Heather J. Dalion, Cristian Rodriguez-Aguayo, Ricardo J. Fernandez-de Thomas, Burcu Aslan, Paloma del C. Monroig, Guermarie Velaquez-Torres, Rebecca A. Previs, Sunila Pradeep, Neermin Kahraman, Huamin Wang, Pinar Kanlikilicer, Bulent Ospolat, Sean C. Cho, urząd, Guido Reifenberger, and Jasdeep K. Saggar

2091 EMERGENCE OF MULTIPLE EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martinez, Israel Canadias, Luca Lazzari, Noelia Fernuz, Mariangela Russo, Sandra Misale, Iria Gonzalez, Mar Iglesias, Elena Cavilan, Giorgio Corti, Sebastian Hobor, Giovanni Cisafulli, Marta Salido, Juan Sanchez, Alba Dalmases, Joaquín Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut

2094 THE IMPACT OF CLONE SIZE ON THE PROGNOSTIC VALUE OF CHROMOSOME aberrations BY Fluorescence IN SITU Hybridization in Multiple Myeloma
Gang An, Zengui Li, Yu-Zhu Tai, Chirag Aharya, Qian Li, Xiaoqi Qin, Shuhua Yi, Yan Xu, Xiaoyan Feng, Chengwen Li, Jiawei Zhao, Lihui Shi, Meirong Zhang, Shuhui Deng, Weiwei Su, Mu Hao, Dehui Zou, Youzhong Zhao, Junyuan Qi, Tao Cheng, Kun Ru, Jianxiang Wang, Kenneth C. Anderson, and Lugui Qiu

2087 EMERGENCE OF MULTIPLE EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martinez, Israel Canadias, Luca Lazzari, Noelia Fernuz, Mariangela Russo, Sandra Misale, Iria Gonzalez, Mar Iglesias, Elena Cavilan, Giorgio Corti, Sebastian Hobor, Giovanni Cisafulli, Marta Salido, Juan Sanchez, Alba Dalmases, Joaquín Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut